Gossamer Bio, Inc.

GOSS Nasdaq SEC CIK 1728117
Follow Gossamer Bio Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $38.4M +189.1% vs same quarter last year
Net income −$48.1M +0.3% vs same quarter last year
EPS, diluted −$7.36 +56.5% vs same quarter last year
Operating cash flow −$29.6M +18.2% vs same quarter last year
Revenue by quarter
$9.4M
$9.9M
$11.5M
$13.3M
$13.8M
$17M
$9.2M
$38.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100M$200MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$48.5M−$170.4M
FY24$114.7M−$56.5M
FY23$0−$179.8M
FY22$0−$229.4M
FY21-−$234M
FY20-−$243.4M
FY19-−$180.3M
FY18-−$147M
FY17-−$6.8M
FY16--
Free cash flowOperating cash flow minus capital expenditure
−$200M−$150M−$100M−$50M$0FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$171.3M
FY24−$3.5M
FY23−$159.2M
FY22−$187.4M
FY21−$190.4M
FY20−$177.9M
FY19−$147.8M
FY18−$54.5M
FY17-
FY16-